EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Computational Prediction of Immunogenic Epitopes and Protein Structures of Heat Shock Protein 90 in Toxoplasma gondii

Amirhossein Abedi, Ali Dalir Ghaffari, Sobhan Dehghanpour, Mohammad Fekrikia

Immunity, Inflammation and Disease · 2026-11 · 14 (11)

DOI: 10.1002/iid3.70584 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Introduction Toxoplasma gondii ( T. gondii ) is an obligate intracellular protozoan parasite that poses a significant threat to both human and animal health worldwide. Despite extensive research efforts, no effective vaccine is currently available for human use. Heat shock protein 90 (Hsp90) is a highly conserved molecular chaperone essential for protein folding, signal transduction, and stress response regulation in T. gondii . Due to its immunological importance and developmental regulation, Hsp90 is a promising target for vaccine development. Material and Methods In the present study, comprehensive immunoinformatics approaches were employed to characterize T. gondii Hsp90. Various bioinformatics tools were used to analyze its physicochemical properties, subcellular localization, post‑translational modifications, structural features, and potential immunogenic epitopes. Results The protein comprised 708 amino acids, had a molecular weight of 81.93 kDa, and was predicted to be unstable, soluble, and nonallergenic. Structural modeling and validation revealed that 50.85% of the residues form α‐helices, and 15.68% β‐strands, with two disulfide bonds contributing to conformational stability. Multiple bioinformatics tools identified several B‐ and T‐cell epitopes with high antigenicity, strong binding affinity to both MHC Class I and II molecules, and favorable immunogenic profiles. The peptide SEDLPLNISRESLQQNKILK obtained the highest predicted B‐cell epitope score using SVMTriP, while ANMERIMKAQALRDN was selected as a promising T‐cell epitope based on MHC‐II binding prediction and VaxiJen antigenicity assessment. The overall antigenicity scores (0.757 for ANTIGENpro and 0.551 for VaxiJen) confirmed Hsp90 as an immunogenic and safe vaccine candidate. Conclusion The findings highlight T. gondii Hsp90 as a promising target for subunit vaccine development, providing a theoretical foundation for future in vitro and in vivo validation studies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →